Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 15/20 | 0.52 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408283 | 0.89 | ESR1 (0.53) | ESR1ESR2ENPP3HDAC1HDAC6 | |
| SCHEMBL2405282 | 0.85 | ESR1 (0.53) | ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL2405285 | 0.85 | ESR1 (0.53) | ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL2405279 | 0.85 | ESR1 (0.53) | ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL2405283 | 0.85 | ESR1 (0.53) | ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL2407131 | 0.83 | ESR1 (0.54) | ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL2407126 | 0.83 | ESR1 (0.54) | ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL2407129 | 0.83 | ESR1 (0.54) | ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL2407123 | 0.83 | ESR1 (0.54) | ESR1ESR2HDAC1HDAC6 | |
| SCHEMBL12318155 | 0.81 | ENPP3 (0.51) | ESR1ESR2ENPP3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | ELOVL5, ELOVL3, ELOVL6 | ESR1 7/4885ESR2 5/4885ENPP3 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.